LAURA CRAIN: Open Payments
NPI 1699449678 · GREENVILLE, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$594 in 25 payments from 8 companies in 2025. Trend: 2023 $232 · 2024 $263 · 2025 $594
Food & beverage: $594
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 5 | $159 |
| E.R. Squibb & Sons, L.L.C. | 5 | $94 |
| Celgene Corporation | 3 | $76 |
| Daiichi Sankyo Inc. | 3 | $68 |
| PFIZER INC. | 3 | $67 |
| Novartis Pharmaceuticals Corporation | 2 | $54 |
| AstraZeneca Pharmaceuticals LP | 2 | $40 |
| Lilly USA, LLC | 2 | $36 |
Products named: Trodelvy, OPDIVO, REBLOZYL, KISQALI, XTANDI, Enhertu, VERZENIO, INJECTAFER.
Industry payments across SC — which companies pay providers there.
